Name: MEDICUS PHARMA LTD (MDCX) Stock
Brand: MEDICUS PHARMA LTD
Rating: 3 (3 reviews)

MDCX Latest News, Press Relases and Analysis

All

Press Releases

7 days ago - By: Chartmill - Mentions: MVO GCO CCRN RGC ...

Let's take a look at the stocks that are in motion in today's session.

6 days ago - By: ACCESS Newswire

Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement

10 days ago - By: ACCESS Newswire

Medicus Pharma Ltd. Appoints Carolyn Bonner as Chief Financial Officer in Addition to Her Role as President

10 days ago - By: Medicus Pharma

Medicus Pharma Ltd. Appoints Carolyn Bonner as Chief Financial Officer in Addition to Her Role as President

17 days ago - By: Medicus Pharma Ltd.

Medicus Pharma Ltd. Explore Novel Treatment Innovations that may Revolutionize Treatments for Prostate and Skin Cancers

17 days ago - By: Medicus Pharma Ltd.

Medicus Pharma Ltd. Explore Novel Treatment Innovations that may Revolutionize Treatments for Prostate and Skin Cancers

24 days ago - By: Medicus Pharma

Medicus Pharma Ltd. Announces Filing of FDA Commissioner’s National Priority Voucher Application (CNPV) for SKNJCT-003 to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

24 days ago - By: Medicus Pharma

Medicus Pharma Ltd. Announces Filing of FDA Commissioner’s National Priority Voucher Application (CNPV) for SKNJCT-003 to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

24 days ago - By: ACCESS Newswire

Medicus Pharma Ltd. Announces Filing of FDA Commissioner's National Priority Voucher Application (CNPV) for SKNJCT-003 to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

a month ago - By: ACCESS Newswire

Medicus Pharma Ltd. Provides Corporate Updates and Reports Third Quarter 2025 Financial Highlights

a month ago - By: ACCESS Newswire

Medicus Pharma Ltd. Receives Full United Kingdom Regulatory and Ethical Approvals To Expand Phase 2 Clinical Study (SKNJCT-003) To Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

a month ago - By: Medicus Pharma

Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for SKINJECT™ in Patients with Gorlin Syndrome

a month ago - By: Medicus Pharma

Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for SKINJECT™ in Patients with Gorlin Syndrome

a month ago - By: ACCESS Newswire

Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for Skinject(TM) in Patients with Gorlin Syndrome

2 months ago - By: ACCESS Newswire

Medicus Pharma Ltd. Announces First Patient Treated in United Arab Emirates (UAE) Sknjct-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

2 months ago - By: ACCESS Newswire - Mentions: COEP QNTM

Three Biotech Companies Redefining Value Creation Through Dual Strategies

2 months ago - By: ACCESS Newswire

Medicus Pharma Ltd. to Present at The Maxim Growth Summit 2025

2 months ago - By: ACCESS Newswire

Medicus Pharma Ltd. to Present at the Family Office Summit in Dubai, UAE

2 months ago - By: ACCESS Newswire

Medicus Pharma Ltd. Receives Positive Feedback From the Food and Drug Adminstration (FDA) Type C Meeting Supporting the Development of Skinject

3 months ago - By: Benzinga - Mentions: SNGX DRIO CLSD CRNX ...

12 Health Care Stocks Moving In Friday's Pre-Market Session

3 months ago - By: ACCESS Newswire

Medicus Pharma Ltd. To Present at Brookline Capital Markets

3 months ago - By: ACCESS Newswire

Medicus Pharma Ltd. Announces $8.0 Million Non-Dilutive Debenture Financing

3 months ago - By: ACCESS Newswire

Medicus Pharma Ltd. Provides Update on United Arab Emirates (UAE) SKNJCT-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

MEDICUS PHARMA LTD (MDCX) Stock News

MDCX Latest News, Press Relases and Analysis